Sheryl Stevenson

Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.

João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means for gene therapy eligibility

John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging therapies including a C1q inhibitor and cell-based options.

A retrospective study of nearly 1,000 patients found epithelial resolution with serial decellularized basement membrane graft use in subclinical to Stage 1 disease.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now.

Matias Iglicki, MD, PhD, on patient selection, technical pitfalls and why symmetry decides outcomes in flanged vs sutured fixation

The Aug. 20-23 meeting in Monterey, California, offers CME across subspecialties alongside sessions on mentorship, career longevity, and research.

CMS payment rates for the FSYX Ocular Pressure Adjusting Pump take effect October 1, 2026, clearing a reimbursement path for the noninvasive glaucoma device.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

Panelists weigh in on treatment goals, access barriers, and where the field is headed.